BioSpace News Archive

Estimated total sales of HEMOBLAST™ Bellows for the first nine months of 2019 are expected to show strong growth at €2.5 million (compared to €1.5 million for the first half of 2019 and €0.6 million for the full year 2018) and are expected to be on track to achieve the 2019 revenue guidance range of €4.0-€4.5 million

GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.

TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.

CELLINK is receiving a patent from the U.S. Patent and Trademark Office for the design of the company’s flagship bioprinter.

According to multiple reports, President Donald Trump is set to pick Hahn, a noted radiation oncologist, as the successor to Scott Gottlieb.

Companies from across the globe share information on their business and pipelines.

StableView Asset Management is a full-service asset and wealth management firm that caters to individual clients and institutional investors.

Results demonstrates that use of KneeKG in patients with osteoarthritis reduces pain, improves patient quality of life, and may reduce need for unnecessary surgery.

Collaboration will leverage Lantern’s proprietary AI platform and NCI’s platform to better predict patients’ tumor responses to specific drug classes and therapeutics

Novadip Biosciences will present a case study highlighting the results of a scaffold-free, 3-dimensional autologous cell therapy for the treatment of critical size bone reconstruction at the European Orthopaedic Research Society 2019 conference in Maastricht, The Netherlands.